Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Mediwound could feel the burn with Nexobrid launch
Mediwound looks set for US approval of its burn therapy Nexobrid, but driving adoption could be the real challenge.
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
